We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Automated Collection of CTCs Improves Prostate Cancer Diagnosis

By LabMedica International staff writers
Posted on 16 Sep 2019
Print article
Image: The Parsortix system for collection of circulating tumor cells (Photo courtesy of ANGLE plc).
Image: The Parsortix system for collection of circulating tumor cells (Photo courtesy of ANGLE plc).
A recent paper described the benefits of circulating tumor cell (CTC) analysis for improving the diagnosis of aggressive prostate cancer beyond currently used PSA (prostate specific antigen) measurement, biopsy and/or MRI imagery.

PSA testing can result in unnecessary biopsies and over-diagnosis with consequent over-treatment. Tissue biopsy is an invasive procedure, associated with significant risk of complications. More accurate non- or minimum-invasive diagnostic approaches are required to avoid unnecessary prostate biopsy and over-diagnosis.

Towards this end, investigators at Queen Mary University of London (United Kingdom) evaluated the potential of using circulating tumor cell analysis for prostate cancer diagnosis, particularly in predicting the presence of clinically significant prostate tumors in patients prior to biopsy.

The investigators used the ANGLE plc (Surrey, United Kingdom) Parsortix system to capture and analyze CTCs from 98 pre-biopsy and 155 newly diagnosed prostate cancer patients.

The Parsortix liquid biopsy process requires a blood sample - typically 10 milliliters in an EDTA vacutainer tube. As no pre-processing is required, the tube is simply attached to the Parsortix instrument. A Parsortix filtration cassette is inserted into the instrument and the system is primed for use. The instrument automatically passes the blood through the filtration cassette, and CTCs are caught in the cassette due to their larger size and lower compressibility as compared to other blood components.

Once trapped in the cassette, CTCs may be automatically stained with selected antibodies, which enables their identification and characterization. In addition, CTCs may be enumerated by placing the filtration cassette under a fluorescent microscope. Alternatively, cells may be eluted from the cassette and recovered in buffer solution for genomic analysis.

Results obtained with the Parsortix system indicated that the appearance of CTCs in pre-biopsy blood samples was indicative of the presence of aggressive prostate cancer. When the CTC tests results were combined with those of the current PSA test, the presence of aggressive prostate cancer in subsequent biopsies was predicted with accuracy of over 90%, better than any previously reported biomarkers.

Senior author Dr. Yong-Jie Lu, professor of molecular oncology at Queen Mary University of London said, "The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and over treatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for better selection of patients to undergo the biopsy procedure. Testing for circulating tumor cells is efficient, non-invasive, and potentially accurate, and we have now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer."

The study was published in the August 7, 2019, online edition of the Journal of Urology.

Related Links:
Queen Mary University of London
ANGLE plc

HLX
Gold Supplier
Virus Detection System
DRI-CHEM IMMUNO AG2
New
PCR Fluorescent Quantitative System
AccuRa mini
New
HLA-B27 Real Time PCR Test
RIDA GENE HLA-B27

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.